We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
+13.35%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.41B
AUM Growth
-$85.8M
Cap. Flow
-$78.4M
Cap. Flow %
-3.25%
Top 10 Hldgs %
66.5%
Holding
55
New
2
Increased
13
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$65M
2
PLRX icon
Pliant Therapeutics
PLRX
+$15.3M
3
KALV
KalVista Pharmaceuticals
KALV
+$12.4M
4
TRVI icon
Trevi Therapeutics
TRVI
+$10.5M
5
PVLA
Palvella Therapeutics
PVLA
+$10M

Top Sells

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$49.7M
2
KRYS icon
Krystal Biotech
KRYS
+$35.5M
3
PCVX icon
Vaxcyte
PCVX
+$33.8M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$30.2M
5
TYRA icon
Tyra Biosciences
TYRA
+$17.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.7%
2 Miscellaneous 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMS icon
1
NewAmsterdam Pharma
NAMS
$3.02B
$409M 16.98%
15,916,418
+3,061,224
+24% +$65M
MIRM icon
2
Mirum Pharmaceuticals
MIRM
$6.11B
$272M 11.28%
6,570,392
– –
VRNA
3
DELISTED
Verona Pharma
VRNA
$157M 6.52%
3,383,950
– –
KRYS icon
4
Krystal Biotech
KRYS
$10.4B
$124M 5.13%
788,460
-200,000
-20% -$35.5M
ARQT icon
5
Arcutis Biotherapeutics
ARQT
$3.05B
$122M 5.08%
8,785,284
– –
IRON icon
6
Disc Medicine
IRON
$3.02B
$111M 4.62%
1,754,834
– –
MBX
7
MBX Biosciences
MBX
$3.02B
$110M 4.58%
5,985,347
– –
RYTM icon
8
Rhythm Pharmaceuticals
RYTM
$7.09B
$105M 4.34%
1,869,808
-547,144
-23% -$30.2M
BBIO icon
9
BridgeBio Pharma
BBIO
$14.8B
$104M 4.33%
3,800,457
+40,000
+1% +$1.03M
TARS icon
10
Tarsus Pharmaceuticals
TARS
$3.93B
$87.9M 3.65%
1,587,527
– –
PHAT icon
11
Phathom Pharmaceuticals
PHAT
$759M
$82.1M 3.41%
10,109,279
– –
ERAS icon
12
Erasca
ERAS
$5.68B
$48.7M 2.02%
19,391,687
– –
PCVX icon
13
Vaxcyte
PCVX
$9.05B
$44.2M 1.83%
539,405
-340,000
-39% -$33.8M
TRVI icon
14
Trevi Therapeutics
TRVI
$2.42B
$43.9M 1.82%
10,664,774
+3,283,684
+44% +$10.5M
RVMD icon
15
Revolution Medicines
RVMD
$45.1B
$43.6M 1.81%
997,455
– –
KALV
16
DELISTED
KalVista Pharmaceuticals
KALV
$41.4M 1.72%
4,887,867
+1,200,000
+33% +$12.4M
AGIO icon
17
Agios Pharmaceuticals
AGIO
$1.98B
$35.2M 1.46%
1,069,754
+25,600
+2% +$1.2M
EWTX icon
18
Edgewise Therapeutics
EWTX
$4.85B
$33.9M 1.41%
1,271,245
-1,561,622
-55% -$49.7M
SLNO
19
DELISTED
Soleno Therapeutics
SLNO
$31.4M 1.3%
699,159
-176,508
-20% -$9.15M
ORIC icon
20
Oric Pharmaceuticals
ORIC
$1.32B
$31.4M 1.3%
3,888,238
-254,617
-6% -$2.34M
RARE icon
21
Ultragenyx Pharmaceutical
RARE
$1.48B
$27.7M 1.15%
658,715
+25,000
+4% +$1.24M
SVRA icon
22
Savara
SVRA
$1.14B
$26.6M 1.1%
8,660,379
+502,994
+6% +$1.75M
CGON icon
23
CG Oncology
CGON
$6.53B
$22.1M 0.92%
770,000
– –
HLVX
24
DELISTED
HilleVax
HLVX
$22M 0.91%
10,617,062
– –
ANAB icon
25
AnaptysBio
ANAB
$1.69B
$20.8M 0.86%
1,573,719
-635,470
-29% -$15.4M
1
2 3

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q4 2024 Portfolio in Review

As of Q4 2024, Frazier Life Sciences Management held 55 positions worth $2.41B, down 3.4% from $2.5B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Frazier Life Sciences Management withdrew a net $78.4M in Q4 2024, closing 5 positions and reducing 9 holdings. Its most notable exit was Tyra Biosciences, an estimated $17.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Frazier Life Sciences Management opened a new position in Pliant Therapeutics worth $14.8M.

  • Frazier Life Sciences Management's largest Q4 2024 buy was Pliant Therapeutics: 1,120,803 shares worth $14.8M.
  • Frazier Life Sciences Management added most to NewAmsterdam Pharma in Q4 2024, an estimated $65M increase.
  • Frazier Life Sciences Management's biggest Q4 2024 reduction was Edgewise Therapeutics, cutting an estimated $49.7M.
  • Frazier Life Sciences Management fully exited Tyra Biosciences in Q4 2024, selling an estimated $17.2M.
  • Frazier Life Sciences Management's ten largest holdings make up 67% of its $2.41B portfolio in Q4 2024.
  • Frazier Life Sciences Management opened 2 new positions and closed 5 in Q4 2024.
  • Frazier Life Sciences Management's portfolio value fell 3.4% quarter-over-quarter to $2.41B.

Based on Frazier Life Sciences Management's 13F filing for Q4 2024, filed 18 Feb 2025.